Lexaria Bioscience Corp — 四半期貸借対照表 (NASDAQ:LEXX) | MetaTrader

チャート全体を表示

ニュース

Lexaria、薬物送達技術の2026年研究プログラムを開始

Lexaria launches 2026 research program for drug delivery tech

レクサリア・バイオサイエンス株主、年次総会で取締役選任と監査役を承認

Lexaria Bioscience shareholders approve board elections and auditor at annual meeting

レクサリアのDehydraTECH、GLP-1薬の副作用を軽減

Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Abivax (NASDAQ:ABVX), Rich Sparkle Holdings (NASDAQ:ANPA)

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Agios Pharmaceuticals (NASDAQ:AGIO), Capital One Finl (NYSE:COF)

レクサリア・バイオサイエンスの株価目標、H.C.ワインライトが4ドルから1.50ドルに引き下げ

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright

DehydraTECH-セマグルチド、Rybelsuと比較して副作用48%減少

DehydraTECH-semaglutide shows 48% fewer side effects than Rybelsus